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Abstract
The public health impact of a harmful exposure can be quantified by
the population-attributable fraction (PAF). The PAF describes the at-
tributable risk due to an exposure and is often interpreted as the propor-
tion of preventable cases if the exposure could be extinct.
Difficulties in the definition and interpretation of the PAF arise when
the exposure of interest depends on time. Then, the definition of exposed
and unexposed individuals is not straightforward.
We propose dynamic prediction and landmarking to define and estimate
a PAF in this data situation. Two estimands are discussed which are
based on two hypothetical interventions that could prevent the exposure
in different ways.
Considering the first estimand, at each landmark the estimation prob-
lem is reduced to a time-independent setting. Then, estimation is simply
performed by using a generalized-linear model accounting for the current
exposure state and further (time-varying) covariates. The second estimand
is based on counterfactual outcomes, estimation can be performed using
pseudo-values or inverse-probability weights.
The approach is explored in a simulation study and applied on two data
examples. First, we study a large French database of intensive care unit
patients to estimate the population-benefit of a pathogen-specific inter-
vention that could prevent ventilator-associated pneumonia caused by the
pathogen Pseudomonas aeruginosa. Moreover, we quantify the population-
attributable burden of locoregional and distant recurrence in breast cancer
patients.
keywords: Attributable risk; Competing risks; Dynamic prediction;
Landmarking; Time-dependent exposure;
1 Introduction
A critical aspect of understanding the consequences of an exposure is the harm it
causes for the entire population under study. Whereas the relative risk (RR), and
the odds ratio (OR) are commonly used to quantify the risk increase at the in-
dividual level, the population-attributable fraction (PAF) quantifies attributable
risk at the population level. The PAF is defined as the proportion of attributable
cases due to exposure and is often interpreted as the proportion of preventable
cases if the exposure were extinct.
The PAF was initially defined for basic study designs such as cohort stud-
ies of fixed length ([1]). However, data situations are often more complex. For
example, in hospital epidemiology the goal may be a quantification of the bur-
den of hospital-acquired infections (HAIs). As HAIs occur over the course of
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hospital stays, patients are naturally unexposed at time of admission to the hos-
pital. The time-dependency of exposure makes it difficult to define the group of
patients who are considered to be unexposed. For example, treating eventually
exposed patients as exposed since study entry results in the immortal time bias
([2]). Moreover, as the outcome of interest is often death in the hospital, dis-
charge alive must be considered as a competing event ([3]). Finally, adjustment
for confounding is essential to draw causal conclusions from observational data.
Since the kind of exposure we consider depends on time, we must also consider
time-varying confounding. Corresponding adjustments appear challenging due to
collider-stratification bias ([4]).
The concept of the PAF has been extended to accommodate time-to-event
data with an exposure that is fixed at baseline ([5, 6, 7, 8, 9]). Extensions of
the PAF to data settings with a binary time-dependent exposure and competing
risks have been proposed by [10] and [11]. Both proposed estimands are cumu-
lative measures of attributable risk over the course of time. Thus, they provide
information on the evolution of the PAF for the complete target population. As
a consequence, the effect of a preventive intervention for the subgroup of individ-
uals who are still at risk at later time points may be precluded by the cumulative
nature of the estimands.
In this article, we propose two novel estimands of the PAF that account
for a time dynamic target population. Being based on dynamic prediction and
landmarking ([12]), the estimands allow for a differentiation between individuals
with differing durations at risk. These patients may differ strongly due to evolving
patient characteristics. Consider, for example, a population of ICU patients.
Patients being a long time at risk – so-called long-stayers – are often sicker and
also longer at risk to acquire the exposure (e.g. an HAI).
The first proposed estimand is based on a hypothetical intervention that is
only effective at the actual time of intervention. The estimand is defined over
a specific time window within the study time scale. It summarizes the effect
of intervention within this specific time frame rather than over the complete
follow-up time. A fixed time window is less dependent on the arbitrary end of
follow-up time point, which depends on the patients in the study. The second
estimand is based on an intervention that is effective for a certain amount of time.
Thus, this estimand allows for more realistic long-term intervention relaxing the
assumptions of the first estimand. Moreover, it is also defined over a specific time
window.
After an introduction of the methods, we present the results of a simulation
study in which we investigate the behaviour of the estimands and estimators.
Subsequently, the approaches are applied to a real data sample of ventilated
patients in intensive care. This patient population is at high risk of acquiring
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ventilator-associated pneumonia (VAP) [13]). VAPs are predominantly caused
by the pathogen Pseudomonas aeruginosa (Pa). To understand the potential
benefit of pathogen-specific intervention programs, we study the percentage of
preventable deaths of ventilated patients in the ICU if VAP caused by Pa could
have been avoided.
The method devised in this article is motivated by a particular data example.
However, it is applicable to any other data setting with binary time-dependent
exposure. Therefore, we also apply the method within a different data con-
text. Based on the study of [14] on breast cancer in the TEAM trial data, we
estimate the proportion of attributable death cases due to distant and locore-
gional recurrence. The data example serves as a demonstration of alternative
adjustment methods and is an application in basic survival settings with inter-
nal time-dependent exposures but no competing risks. The article ends with a
discussion.
2 The population-attributable fraction for co-
hort studies of fixed length with a baseline
exposure
The PAF has been defined by [15] as
PAF =
P (D = 1)− P (D = 1|E = 0)
P (D = 1)
, (1)
whereD is the random variable of a dichotomous outcome and E of a dichotomous
exposure. The realization of both D and E is observable. The proposed estimand
is valid for cross-sectional studies and cohort studies of fixed length with a baseline
exposure.
The PAF is usually estimated with observational data, as the effect of the
exposure is generally considered to be harmful. Therefore, adjustment for con-
founding is essential to obtain an unbiased estimate of the population-attributable
burden.
[16] showed that with P (D = 1) = P (E = 1)P (D = 1|E = 1) + P (E =
0)P (D = 1|E = 0) an equivalent definition of the PAF is
PAF = P (E = 1|D = 1)× RR− 1
RR
, (2)
where
RR =
P (D = 1|E = 1)
P (D = 1|E = 0) .
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This reformulation of the PAF allows for a straightforward way of adjusting the
estimator of the PAF by plug-in of an adjusted RR in definition (2) ([16]). The
prevalence of the exposure among cases, P (E = 1|D = 1), can be estimated by
the population average without further consideration of confounders ([16]).
3 Conventional dynamic prediction and land-
marking to estimate the population-attributable
fraction
Dynamic prediction and landmarking implies that estimands are defined for a set
of time points (landmarks) during follow-up. This allows for an update of the
target population that is still at risk at the specific landmark (LM). At each LM
only those individuals at risk are considered, and their exposure state and other
patient characteristics are updated at each LM. Thus, at each LM a different
target population is being considered.
A major strength of conventional dynamic prediction and landmarking is the
facility of adjustment for confounding of the estimator. At each LM the data
situation is reduced to a time-independent setting. The resulting estimand differs
from definitions (1) and (2) only by the target population. Thus, adjustment for
confounding is based on established methods available for estimands that ignore
time of exposure and outcome, such as the approach proposed by [16].
3.1 Formal definition of PAFLM,h
The estimand PAFLM,h consists of a set of separate estimands PAF (l, h). These
depend on a specific landmark l and a time window h and are formally given by
PAF (l, h) =
P (Dl,h = 1|Al = 1)− P (Dl,h = 1|El = 0, Al = 1)
P (Dl,h = 1|Al = 1) , (3)
where Al is the random variable denoting the patients’ at-risk state at l, El is
the random variable of the exposure state at l, and Dl,h is the random variable
of the occurrence of the outcome within (l, l + h].
Since P (Dl,h = 1|Al = 1) = P (El = 1|Al = 1)P (Dl,h = 1|El = 1, Al =
1) + P (El = 0|Al = 1)P (Dl,h = 1|El = 0, Al = 1), an equivalent definition of
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PAF (l, h) is
PAF (l, h) = P (El = 1|Al = 1, Dl,h = 1)× RRl,h − 1
RRl,h
= PEl ×
RRl,h − 1
RRl,h
(4)
with PEl being the prevalence of the exposure at time l among cases occurring
within the time window (l, l + h] and RRl,h is the RR of the outcome within
(l, l + h] depending on the exposure state at time point l, i.e.
RRl,h =
P (Dl,h = 1|Al = 1, El = 1)
P (Dl,h = 1|Al = 1, El = 0) . (5)
Formally, we define by PAFLM,h the set of the PAF (l, h)s over all LMs, i.e.
PAFLM,h = {PAF (l, h)|l ∈ LM}, where LM is the set of chosen LMs and h is
the length of the time window.
3.2 Estimation of PAF (l, h)
For estimation, the LMs should be chosen based on the number of exposed and
unexposed patients at each time point. The number in both patient groups should
be sufficiently large for inference. The time window of fixed length can be defined
based on clinical knowledge and relevance. Examples of how to choose the LMs
and time windows are presented in Sections 5 to 7 based on a simulation study
and real data examples.
Inference at a LM l is performed on a LM dataset ([12]) which consists of all
patients who are still at risk at the LM. For every patient within the LM dataset
the exposure state at the LM as well as the event state at the end of the time
window is accessed. Patients who do not experience the event of interest within
the time window are implicitly assumed to be either still at risk at the end of
the time window or to have experienced the competing event. The matter of
censoring is discussed at the end of this section.
Using (4) to define PAF (l, h) results in a straightforward approach of adjust-
ment for confounding (see [16]). As explained by [16] and briefly described in
Section 2, PAF (l, h) can be estimated by separately estimating the prevalence
PEl and RRl,h. An estimator that accounts for systematic differences between
exposed and unexposed patients is obtained by adjusting RRl,h at each LM l.
Estimation of the adjusted RRl,h can be performed via maximum likelihood
estimation using a log-model, i.e.
P (Dl,h = 1|Al = 1, El, Zl) = exp(β0l + β1l × El + βTl × Zl), (6)
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where β0l is the intercept at LM l, β1l is the coefficient of the exposure state
at l, βTl is the vector of coefficients of Zl. Zl is a vector of baseline and time-
dependent covariates (with covariate values fixed at time point l) sufficient for
confounder control. The condition Al = 1 is automatically fulfilled, as estimation
is based on the LM dataset. The RRl,h is estimated by exp(β̂1l). The log-model
is implemented in the statistical software R within the function glm ([17]).
The prevalence PEl is simply estimated by the proportion of exposed subjects
among cases. With glm, PEl could, for example, be estimated by
PEl = P (El = 1|Al = 1, Dl,h) = exp(α0l + α1l ×Dl,h), (7)
where α0l is the intercept at LM l and α1l the regression coefficient of Dl,h. An
estimator of the variance fo P̂AF (l, h) is obtained analogously to the variance
estimator of the time-fixed PAF (2) (for details see [18]).
3.2.1 Smoothing methods for the separate PAF (l, h)
For practical reasons [12] propose to smooth the separate estimates of PAF (l, h)
over all LMs. The advantages of smoothing are not only the removal of noise and
the nicer presentation, but also the availability of values of PAFLM,h between
two LM time points. Moreover, depending on the smoothing method used, an
increase in efficiency can be achieved.
In principle, two approaches can be used to obtain a smooth curve that in-
terpolates the separate quantities PAF (l, h) over all LMs l, l ∈ LM. An ad hoc
approach is to first estimate PAF (l, h) for each LM separately (as described in
Section 3.2). Then, smoothing splines, regression splines, polynomial regression
or local regression can be used to fit a smooth curve on the separate estimates.
The methods are well described by [19]. The downside of this approach is that
the curve may be easily overfitted, as the choice of the degree of smoothing is not
based on any statistical tests. Therefore, the gain in efficiency is negligible.
As an alternative the principle of pooled logistic regression by a so-called su-
permodel can be used to obtain a smooth curve over all LMs directly without first
fitting the separate models ([12]). Estimation with the supermodel is based on
the LM datasets stacked together to one large dataset. In this ”super prediction
dataset” the patients are represented as often as they appear in the LM datasets
(see [12]). A regression model is fitted on the super prediction dataset separately
for RRl,h and PEl by accounting for possible time-varying effects at the LMs via
interaction terms.
A supermodel for PEl is given by
PEl = P (El = 1|Al = 1, Dl,h) = exp(α0(l) + α1(l)×Dl,h) (8)
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where α0(l) =
∑
α00× f0(l) + ...+ α0K × fK(l) and α1(l) =
∑
α10× g0(l) + ...+
α1K˜× gK˜(l), with f0(l) = g0(l) = 1 and fj(l), gj(l) (1 < j ≤ K or resp. K˜) being
smooth basis functions of the LMs l, l ∈ LM. We choose our basis functions as
proposed in most papers about dynamic prediction and landmarking ([20, 21, 22]).
Thus, K = K˜ = 2 and f1(l) = g1(l) = l, f2(l) = g2(l) = l
2. This results in the
following supermodel
PEl = exp(α00 + α01l + α02l
2 + α10 ×Dl,h + α11l ×Dl,h + α12l2 ×Dl,h). (9)
We use the same basis functions to estimate RRl,h:
P (Dl,h = 1|Al = 1, El, Zl, l) = exp(β0(l) + β1(l)× El + βT × Zl), (10)
with β0(l) = (β00 + β01l + β02l
2) and β1(l) = (β10 + β12l + β12l
2). For simplicity
we do not include any time-varying effects for the covariate vector Zl. RRl,h is
now estimated by exp(β̂1(l)), where l is any time point between the first and the
last LM. The intercept function β0(l) models the baseline risk of experiencing
the event of interest within the time interval, given alive and at risk at the LM.
When including an interaction term for the intercept, we assume that the risk
of experiencing the event of interest within the time interval changes with time.
The effect of acquisition of exposure is modelled by the regression coefficients
β1(l). If interaction terms with the LMs are included, we assume a change of
the effect of the exposure with time. Whether interaction terms with the LMs
are needed and up to which degree can be tested with the Wald test ([12]).
Finally, a smoothed estimate of PAFLM,h is obtained by plugging the estimates
of PEl and RRl,h obtained with the supermodel into equation (4). For both
discussed smoothing approaches, we propose to obtain confidence intervals (CIs)
by a bootstrap approach.
3.2.2 Dealing with censored observations
The method explained so far is valid in the presence of competing risks but
without censoring. Then, the outcome Dl,h is observable for all patients. In hos-
pital epidemiology, this is a common data set up. To generalize the estimation
approach to data settings subject to censoring, dynamic pseudo-observations pro-
posed by [22] can be used. After the pseudo-values have been obtained, the same
method as described above (i.e. the approach by [16]) can be applied.
Dl,h can be also expressed in terms of a survival probability [22]. Let J
denote the number of different event types and let X indicate the type of the
event. Without loss of generality, we assume J = 2 and X = 1 for the event of
interest. We have Dl,h = I(T ≤ l + h,X = 1|T > l), where T is the minimum
of the event and censoring time. A pseudo-value for Dl,h is obtained within the
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LM dataset at l. For an individual i at risk at LM l the pseudo-observation is
defined as
θˆil,h = nlFˆ1(l + h|l)− (nl − 1)Fˆ (−i)1 (l + h|l), (11)
where nl is the number of patients at risk at l, Fˆ1(l + h|l) is the Aalen-Johansen
estimator for the conditional cumulative incidence function P (T ≤ l + h,X =
1|T > l), and Fˆ (−i)(l + h|l) is the according Aalen-Johansen estimator based
on the LM data set at l leaving out observation i. As suggested by [21] the
pseudo-observations can be easily obtained with the R package pseudo ([23]), or
alternatively with the R package prodlim ([24]).
Given the LMs satisfy that the time window (l, l + h] does not exceed the
study horizon τ with both the probability of censoring and the probability of still
being at risk exceeding zero beyond τ , [22] derive asymptotic properties for the
dynamic pseudo-observations. With these properties, they show that estimation
of PEl and RRl,h can be performed in the same way explained above for both
the separate models and the supermodel based on the pseudo-observations. This
also applies to the variance estimators. Then, an estimate of PAF (l, h) and the
variance can be obtained by plug-in of the estimators of RRl,h and PEl .
An alternative way to handle censored observation is the use of standard
survival analysis methodology. This approach is based on definition (4). The
marginal risk P (Dl,h = 1|Al = 1) and the conditional risk P (Dl,h = 1|Al =
1, El = 0) can both be estimated with the Aalen-Johansen estimator. Adjustment
is possible, for example, with the Cox proportional hazards model. This approach
is explained in detail by [20]. We also refer to Section 7 where we apply this
approach to a specific data example.
4 A counterfactual approach to define the population-
attributable fraction
The estimand PAFLM,h is interpretable as the percentage of preventable cases
if the exposure could be eliminated at the LM. However, interventions often
have a long-term effect. Thus, a possibly more desirable interpretation could be
’the proportion of preventable cases if the exposure could be avoided over the
entire time interval [l, l + h]’. We denote the estimand with this interpretation
by PAF0(l, h) and the set of estimands over a range of LMs l by PAF0LM,h. A
graphical illustration of the interventions assumed for PAFLM,h and PAF0LM,h
is given in Figure 1.
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4.1 Formal definition of PAF0LM,h
Formally, PAF0(l, h) can be defined as
PAF0(l, h) =
P (Dl,h = 1|Al = 1)− P (D0l,h = 1|Al = 1)
P (Dl,h = 1|Al = 1) . (12)
P (Dl,h = 1|Al = 1) is the (observable) overall risk of experiencing the event of
interest within the time window (l, l+h] among patients still alive at l. P (D0l,h =
1|Al = 1) is the hypothetical risk of experiencing the event of interest within
(l, l+h] among patients still alive at l had the exposure been removed within the
time window [l, l + h] for all patients who were still at risk at l.
We expressed PAF0(l, h) with marginal outcome risks. This definition corre-
sponds to definition (3) of PAF (l, h). PAF (l, h) was also expressed in terms of
RR and prevalence, which is defined by the conditional outcome risks. The two
definitions (3) and (4) are equivalent. This is due to the fact that the exposure
state is fixed at LM l. In contrast, PAF0(l, h) cannot be reformulated in terms of
RR and prevalence, because the reformulation uses information about the preva-
lence within the time window which is unknown at l. Formally, we would need
P (Dl,h = 1|Al = 1, El = 0) = P (D0l,h = 1|Al = 1), which is not the case if some
patients acquire the exposure within the window (l, l + h] (post time point l).
4.2 Estimation of PAF0(l, h)
To estimate PAF0(l, h), we separately estimate P (Dl,h = 1|Al = 1) and P (D0l,h =
1|Al = 1) and plug them into equation (12). Estimation of the observable
marginal risk P (Dl,h = 1|Al = 1) is straightforward by maximum likelihood
estimation based on generalized linear models (glms). A possible model is
P (Dl,h = 1|Al = 1) = expit(β0l). (13)
In this situation other link functions such as the link function exp would return
identical results.
Estimation of the hypothetical risk of the outcome had all patients been un-
exposed, P (D0l,h = 1|Al = 1), is complicated by the missing values of exposed
patients. Given consistency the counterfactual random variable of the event of
interest had the exposure been removed, D0l,h, is only realized for patients who
were factually observed to remain unexposed within [l, l + h]. For patients who
acquire the exposure within the time window the realization of D0l,h is not ob-
servable. Therefore, it must be imputed based on the information available for
patients who were observed to remain unexposed within [l, l + h].
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To impute the missing outcomes of exposed patients various approaches are
possible. In the following, we first explain how to use a pseudo-value approach
similar to Section 3 where this approach was used for the imputation of missing
outcomes due to censoring. With this approach, adjustment for time-dependent
covariates updated at each LM is possible. However, in contrast to the estima-
tion of PAFLM,h, which assumes an intervention that is effective at the LM only,
unbiased estimation of PAF0LM,h requires patients to be comparable within the
complete time window h and not just at the LM l. Therefore, adjustment for
time-varying confounding within the time window might become necessary. Ad-
justment for time-varying confounding can be done using inverse-probability of
exposure weights. This procedure is also explained below.
We first explain the pseudo-value approach for an estimation of P (D0l,h =
1|Al = 1). In principle, we do the same as in Section 3.2.3. However, instead of
dealing with outcomes that are missing due to censoring, we aim to impute the
outcomes of patients who acquired the exposure within the time window. The
crucial assumption is that patients who did not acquire the exposure within the
time window are comparable to those patients who did acquire it.
An estimator of P (D0l,h = 1|Al = 1) can be obtained by treating patients
who acquire the exposure within the time window as censored. We express the
realization of D0l,h by I(T0 ≤ l + h,X = 1|T > l), where T0 is the minimum of
the event and exposure time and X is, as in Section 3.2.3., the event indicator
(i.e. X = 1 if the patient experienced the event of interest in (l, l + h], X = 2
if the patient experienced the competing event). Then, the pseudo-value of D0l,h
for patient i is defined as
θˆi0l,h = n
0
l Fˆ
0
1 (l + h|l)− (n0l − 1)Fˆ 0(−i)1 (l + h|l), (14)
where n0l is the number of patients being unexposed and at risk at time point l,
Fˆ 01 (l + h|l) is the Aalen-Johansen estimator for the conditional cumulative inci-
dence function P (T0 ≤ l + h,X = 1|T > l) and Fˆ 0(−i)(l + h|l) is the according
Aalen-Johansen estimator based on the LM data set at l leaving out observation
i. In contrast to the pseudo-values in Section 3.2.3., θˆi0l,h is estimated with the
patients that are unexposed at LM l. In Section 3.2.3., pseudo-values were es-
timated with all patients at risk at l. This is because we address two distinct
problems. In Section 3.2.3. the observable realization of the random variable
Dl,h was missing due to censoring. Here, we aim to estimate pseudo-values for
D0l,h by assuming that patients who acquire the exposure within the time win-
dow (l, l + h] would have the same risk to experience an event as patients who
remain unexposed. Thus, patients who acquire the exposure must be treated as
censored. After the pseudo-values have been obtained P (D0l,h = 1|Al = 1) can
be also estimated with glms using the R-package geese.
The estimate hereby obtained is most likely biased due to a systematic dif-
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ference between patients who acquire the exposure and patients who remain un-
exposed. Such confounding implies a violation of the assumption that patients
exposed at some time point within [l, l+ h] would have the same risk as patients
remaining unexposed within [l, l + h].
As discussed by [25] and [26], the pseudo-observations are based on the as-
sumption of covariate independent censoring. In the presence of confounding
this assumption is violated. If adjustment for covariates updated at each LM
is sufficient for confounder control, adjustment of P (D0l,h = 1|Al = 1) can be
done by using covariate-adjusted pseudo-values for the estimation with geese.
The adjusted pseudo-values are based on the adjusted Aalen-Johansen estima-
tors Fˆ 01 (l + h|l, El = 0, Zl), where Zl is a vector of covariate values observed at
LM l. Yet up to now, the R functions pseudo ([23]) and prodlim ([24]) are not
implemented for covariate adjusted Aalen-Johansen estimators. Therefore, the
pseudo-values must be adjusted either via stratification or - more sophisticated -
via nearest-neighbour estimation as proposed by [27].
However, with increasing length of the time window h, adjustment for time-
varying confounding becomes necessary. Therefore, we propose to use adjusted
inverse probability of exposure weights as initially proposed by [28]. The approach
is similar to the modified sequential Cox approach proposed by [29]. The weights
are estimated separately for each LM dataset using the R package ipw. Then,
based on the LM datasets, two weighted cause-specific Cox regression models –
one for the occurrence of the event of interest within the time window and one
for the occurrence of the competing event within the time window – are used to
estimate the effect of the exposure within the time window. This can be done
with the R function coxph of the survival package ([30]). Patients who remain
at risk until l + h are administratively censored at the end of the time window.
Finally, P (D0l,h = 1|Al = 1) can be estimated using the two Cox regression
models and the R function survfit. A detailed description of this procedure is
provided in the tutorial by [31] and the Appendix of [32]. To obtain appropriate
CIs, we propose to use a bootstrap method. Smoothed estimates can be obtained
as explained in Section 3.
5 Simulation study
In a simulation study, we investigated the performance of the two proposed es-
timands and their estimators. It serves as an exemplary presentation of the two
approaches under controllable conditions. In the following, we present two simula-
tion scenarios. Other simulations based on different models have been performed.
They led to the same conclusions and are not presented here.
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The two simulation scenarios were based on a multi-state model considering
the binary time-dependent exposure as an intermediate event. The final ab-
sorbing states were the event of interest and a competing event (see Figure S1
in the online supplementary material). The resulting model is often called ex-
tended illness-death model. A detailed description of the model is given by [33].
Both estimands, PAFLM,h and PAF0LM,h, can be identified with the transition
probabilities of the extended illness-death model which are fully defined by the
cause-specific hazard rates ([34]).
We considered constant cause-specific hazards and time-varying Weibull haz-
ards. The R code for the simulation study was based on the code by [35]. The
sample sizes were 2,000 and 10,000 observations. Both simulation scenarios have
been run 100 times. For both scenarios and each run, we obtained separate and
smoothed estimates of both PAFLM,h and PAF0LM,h. Estimation of PAFLM,h
was performed as described in Section 3. We did not model any confounding
in the simulation study. Therefore, estimation of PAF0LM,h was based on the
unadjusted pseudo-value approach explained in Section 4. Smoothed estimates
of PAFLM,h and PAF0LM,h were obtained via the supermodel approach. The
results of each scenario were summarized as plots of the mean, median, and the
first and third quartiles of the 100 runs at each LM.
First, we considered a no-effects model meaning, that the exposure does not
increase the risk of the event of interest. The no-effects model was simulated with
constant hazards. Second, the effect of the exposure was modelled such that it
increased the risk of the event of interest directly via an increased hazard of the
event of interest. This scenario was based on time-varying cause-specific hazards.
The Weibull hazards of this scenario are shown in Figure 2.
The choice of LMs and the time window were based on the data situation.
The LMs were chosen such that there were at least 20 observations of exposed
and unexposed patients at each LM. The time window was chosen as the mean
time at risk. For the time constant-hazards data setting this was 30 time points.
In the time-varying-hazards data setting events occurred earlier and the mean
duration at risk was eight time points.
In the no-effects model both PAF0LM,h and PAFLM,h were approximately zero
(Figure 3). In the other scenario, PAF0LM,h was larger than PAFLM,h (Figure 4).
If exposure could be prevented over the complete considered time window and
exposure increases the risk of the event of interest, then at least as many cases
are preventable as in a setting where exposure can be only prevented at the LM.
Performance of the estimators varied with sample size at the LMs. Com-
pared to the full cohort there is a significant reduction of patients being exposed
and unexposed at the LMs and the number of events occurring in each group.
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Therefore, variation was considerably large (see Figure 3 and 4).
The smoothed versions of P̂AFLM,h and P̂AF 0LM,h did reduce the variability
of the separate estimates, but not considerably. Despite the smoother presenta-
tion of the estimates, the simulation study did not show a benefit of the super-
model that would justify the more complex estimation procedure. However, we
emphasize that our simulation study does not allow for a generalization of these
findings. In Section 6, we further discuss the supermodel in the context of the
data example. Source code to reproduce the results is available as Supporting
Information on the journals web page.
6 Data example: Preventable death cases among
ventilated patients in intensive care
The prevention of hospital-acquired infections caused by multi-drug resistant
pathogens is of major interest to public health. In the following, we investi-
gate the OUTCOMEREA French multi-center database. We consider a sample
of 7221 invasive-mechanically ventilated (IMV) patients to understand the bur-
den of ventilator-associated pneumonia caused by the pathogen Pseudomonas
aeruginosa (V APP.a.) on a population level. Patients are considered at risk of
V APP.a. acquisition after two days of IMV. Follow-up was from first day of IMV
to death in the ICU (n=1971) or discharge alive from the ICU (n=5250). Follow-
up was complete. However, discharge alive must be considered as competing
risk to death in the ICU. Moreover, all patients who enter the study are initially
unexposed, V APP.a. is a time-dependent exposure. By the end of follow-up, 463
patients had acquired a V APP.a..
In a previously published competing risks analysis we found that patients with
a V APP.a. have an increased risk of death in the ICU due to a prolonged length of
stay ([36]). Thus, while there was no direct effect on the death hazard (adjusted
hazard ratio (adjHR)=1.05; 95%CI [0.88;1.26]), the hazard of discharge alive was
significantly reduced for an infected patient (adjHR=0.67; 95%CI [0.50;0.79]) (see
[36]).
To understand the public health impact of V APP.a. for mechanically ven-
tilated patients in intensive care, we estimated both PAFLM,h and PAF0LM,h.
The two approaches allow for a differentiation between ’short-stayers’ and ’long-
stayers’. While most patients leave the ICU after a few days, some patients stay
for quite some time. These long-stayers are at higher risk of V APP.a. acquisition.
At the same time, patients are most vulnerable in the first days of IMV. Our
approach reveals which patient population would benefit most from a preventive
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intervention.
The LMs were chosen daily from day three to day fifty, which is the time
frame in which a considerable number of patients were still at risk. The time
window was the mean length of stay in the ICU which is 15 days. Figure 5 shows
the number of patients at risk among the unexposed and exposed patients at each
LM, as well as the number of events occurring within the time window.
We estimated both unadjusted and adjusted versions of PAFLM,h and PAF0LM,h.
To account for major differences between infected and uninfected patients, we
adjusted for the baseline confounding factors ’type of patient’ (surgical versus
medical) and age at study entry. Moreover, we adjusted for the time-varying
sepsis-related organ failure assessment (SOFA) score, which is an indicator for
the patients’ severity of the initial illness. To estimate PAFLM,h, the SOFA score
was updated at each LM and held fixed over the time window. In contrast,
when estimating PAF0LM,h, time-varying confounding due to the variation of
the SOFA score within the time window must be accounted for. Therefore, we
adjusted PAF0LM,h for the time-varying SOFA score. To further avoid collider-
stratification bias we used the values lagged by two days. Estimation of PAFLM,h
was performed as described in Section 3. To estimate PAF0LM,h we accounted
for time-varying confounding within the time window. Therefore, we used the
inverse- probability weights as explained in Section 4.
To demonstrate the performance of the supermodel on the data example, we
obtained smoothed estimators of PAFLM,h using polynomials of degree two as
smoothing functions. Thus, we included interaction terms for the baseline risk
and for the infection risk. The resulting model is the one presented in Section 3.
To derive PAFLM,h we also estimated RRl,h. The unadjusted RRl,h (for all
LMs l, l ∈ LM) and PAFLM,h (separate models and supermodel) are shown in
Figure 6. We observe an increased RR of death for patients still in the ICU at day
38 (R̂R38,15 = 1.7, 95%-CI [1.02; 2.88], separate models). Due to this increased
RR the PAF (separate model) also has a peak at day 38 (P̂AF (38, 15) = 0.13,
95%-CI [−0.024; 0.27]). The zero is contained in the 95%-CI. This implies that
there is no statistical evidence for attributable mortality of V APP.a. within 15 days
for patients in the ICU at day 38. In general, there is no evidence for attributable
mortality within 15 days at any of the LMs, if the reference population are those
patients that are unexposed at the LM.
The supermodel for both RR and PAFLM,h clearly increases the efficiency
of the estimator. The point-wise CIs are considerably smaller. Nevertheless, the
supermodel has some drawbacks. The supermodel puts more weight on LMs with
many patients at risk. As the sample size is decreasing with time, more weight is
put on early LMs. The separate models of R̂RLM,h indicate two peaks at day six
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and day 38. Due to the smaller sample size at day 38, the supermodel does not
follow this trend. The data example demonstrates that the supermodel should
be interpreted in combination with the separate models.
The left panel of Figure 7 shows the unadjusted estimates of PAFLM,h and
PAF0LM,h (separate models). P̂AF 0LM,h indicates attributable mortality within
15 days at LMs nine (P̂AF 0(9, 15) = 0.028, 95%-CI [0.004; 0.05]), ten (P̂AF 0(10, 15) =
0.027, 95%-CI [0.002; 0.05]), and eleven (P̂AF 0(11, 15) = 0.03, 95%-CI [0.002; 0.06])
if the reference population are those patients that are unexposed within [l, l+h].
For example, if V APP.a. could be avoided between days 11 to 26 for patients still
in the ICU at day 11, then 3% of the death cases occurring within this time
window could be prevented. This corresponds to a total number of 25 cases.
Nevertheless, as the prevalence of V APP.a. is – from a statistical point of view –
very low, there is no remarkable difference between P̂AFLM,h and P̂AF 0LM,h.
The adjusted versions of P̂AFLM,h and P̂AF 0LM,h are shown in the right
panel of Figure 7. The estimates reveal that the patient populations are most
vulnerable within the first days of IMV (days three to twelve). Here targeted
preventive interventions against V APP.a. with a long term effect of 15 days would
provide the most benefit. A plot that contrasts the adjusted versions of P̂AFLM,h
and P̂AF 0LM,h with the unadjusted ones is provided in the online supplementary
material in Figure S2. Source code to reproduce the results is available as Sup-
porting Information on the journals web page.
7 Data example: TEAM trial data
[14] studied the risk of death for a sample of the Tamoxifen Exemestane Adju-
vant Multinational (TEAM) trial. The randomized clinical trial included Belgian
and Dutch early breast cancer (BC) patients that were postmenopausal hormone
receptor-positive (HR+) and treated with endocrine. Fontein et al. used dy-
namic prediction and landmarking ([12, 14]) for survival prognosis being made
months past time of diagnosis. The approach accounts for time-varying effects
and allows for an update of patients characteristics recorded past baseline. [14]
found a highly significant increase in all-cause mortality for patients experiencing
locoregional recurrence (LRR) or distant recurrence (DR).
We extended the analysis to study the population-attributable burden of LRR
and DR. The outcome of interest was death of any cause. Thus, in contrast to
the data example in Section 6, we have no competing risks. However, of the
2597 patients included in the analysis, 2238 were censored due to end of follow-
up. Of the initially included patients, 88 eventually experienced LRR and 406
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DR (48 had both LRR and DR, see also the online supplementary material). A
precise clinical definition of LRR and DR is provided by [14]. Both DR and LRR
are time-varying exposures. A multi-state model illustrating the data setting is
provided in the online supplementary material in Figure S3.
To estimate PAFLM,h and PAF0LM,h, we used a time window of five years.
The LMs were chosen at every third month from the second year until the fourth
year since diagnosis. In contrast to [14], we do not consider any LMs before the
first year. Since we use the approach ’dynamic prediction by landmarking’ for
inference rather than prediction a sufficient number of exposed patients should be
present at the LMs. The number of unexposed and exposed patients at each LM
for both exposures (LRR and DR) as well as the number of death cases within
the time window of 5 years is illustrated in bar plots in the online supplementary
material in Figure S4.
We obtained unadjusted and adjusted estimates of PAFLM,h and PAF0LM,h
for both exposures, DR and LRR. To demonstrate different ways of estimation,
estimation of PAFLM,h was based on definition (3) rather than definition (4)
which has been used in the previous data example. The observable overall mor-
tality risk at the LMs within the time window was the same for both estimates,
P̂AFLM,h and P̂AF 0LM,h, and both exposures. Regarding P̂AFLM,h, estimation
of the death risk among unexposed was based on the patients being unexposed
at the LM. Regarding P̂AF 0LM,h, the estimate was obtained by treating patients
experiencing LRR or respectively DR within the time window of five years as ad-
ministratively censored at the time of recurrence. To obtain adjusted estimates,
we adjusted the mortality risk of unexposed patients for each estimand (PAFLM,h
and PAF0LM,h) with the Cox proportional dynamic prediction model as proposed
by [14]. A more detailed explanation is provided in the online supplementary ma-
terial.
The covariates included in the model were age at diagnosis (as continuous
variable, constant and squared), Bloom & Richardson (BR) histological grade
(I, II, III), tumor stage (1,2, 3/4), nodal stage (N0, N1, N2/N3), ER and PR
status (positive, negative), HER2 status (positive, negative, missing), most ex-
tensive surgery (mastectomy, breast conserving surgery), radiotherapy (yes, no).
chemotherapy (yes/no) and treatment status (on/off). Moreover, we adjusted
both PAFLM,h and PAF0LM,h of DR for LRR status at the LM and – as Fontein
et al. – included an interaction term for LRR and LM ([14]). Similarly, we
adjusted PAFLM,h and PAF0LM,h of LRR for DR status at the LM. A detailed
description of the covariates, as well as the regression coefficients of the dynamic
Cox model, can be found in the article by [14].
The adjusted estimates of both PAFLM,h and PAF0LM,h of LRR and DR
are shown in Figure 8. A plot that contrasts the adjusted versions of P̂AFLM,h
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and P̂AF 0LM,h with the unadjusted ones is provided in the online supplementary
material in Figure S5. First, we consider P̂AFLM,h and P̂AF 0LM,h of LRR, which
are shown in the left panel of Figure 8. The estimate P̂AFLM,h is approximately
zero at all LMs but reaches a peak at 2.5 years post randomization. At this
LM only the CI becomes greater than 0. In contrast, an intervention that could
prevent LRR for 5 years would be beneficial at all LMs.
Next, we consider P̂AFLM,h and P̂AF 0LM,h of DR, which are shown in the
right panel of Figure 8. Both types of intervention would be beneficial at all
LMs, with a clear advantage of an intervention that is effective over the next five
years. Then, for example at LM 1 almost 60% (adj. P̂AF 0LM,h ≈ 0.55, 95%-CI
≈ [0.5; 0.6]) of the death cases occurring within five years since the LM would
be preventable. In comparison, only about 12% (adj. P̂AFLM,h ≈ 0.12, 95%-CI
≈ [0.06; 0.18]) would be preventable when the intervention is effective at the LM
only.
With the data example, we demonstrated the application of the proposed
approach for a data setting with a binary time-dependent exposure in a basic
survival setting (no competing risks). To obtain adjusted estimates we used
adjusted survival function based on the Cox proportional hazards model (see
also the online supplementary material). Source code to reproduce the results is
available as Supporting Information on the journals web page.
8 Discussion
This paper introduces a novel approach to define and estimate the PAF for com-
plex data situations. Time-dependent exposures are common in epidemiology.
However, statistical modelling of the time dynamics of exposure and outcome is
challenging and often avoided. Our proposed approach addresses these challenges
in a very basic manner. Nevertheless, it accommodates complex study designs
such as survival data with time-dependent exposure and subject to competing
risks and censoring.
The two proposed estimands, namely PAFLM,h and PAF0LM,h, have a clini-
cally relevant interpretation as they account for the dynamics of the population
over the course time. At a specific LM, PAFLM,h is interpretable as the propor-
tion of preventable cases within a predefined time window if the exposure could
be prevented at the LM. Thus, the estimand is based on a hypothetical interven-
tion that would be effective at time of intervention, i.e. at the considered LM,
only. In contrast, PAF0LM,h, at a specific LM, is interpretable as proportion of
preventable cases within the time window if the exposure could be prevented over
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the complete time window. The assumed intervention has a long term effect over
the complete time window.
Definition of both estimands was based on dynamic prediction and land-
marking ([20]) and estimation was based on existing methods. Adjustment of
PAFLM,h for time-dependent covariates is straightforward since at each LM the
time-dependent data setting is reduced to a data setting with baseline exposure
and fixed length of follow-up. Thus, PAFLM,h retains the advantages of conven-
tional dynamic prediction by landmarking. Since the exposure state is accessed
at the LM only, adjustment for confounding can be performed by updating the
time-dependent patient characteristics at the LM and including these updated
values as time-independent covariates in the model. In contrast, estimation of
PAF0LM,h requires adjustment for time-varying confounding. The time-varying
confounding occurs as individuals must be comparable within the complete time
window. When estimating PAFLM,h individuals must be comparable at the LM
only. As a consequence estimation of PAF0LM,h is more complicated.
Nevertheless, PAF0LM,h relaxes the assumption that the exposure can be pre-
vented at the LM only. Moreover, it overcomes the limitation of data samples in
which many individuals acquire the exposure at later LMs. In the conventional
approach, used to define PAFLM,h, these individuals are considered unexposed at
the early LMs. If the exposure is harmful, the individuals who acquire exposure
within the time window increase the risk among unexposed and therefore poten-
tially preclude the burden of the exposure at earlier LMs. Our data examples in
Section 6 and 7 demonstrated that this effect is negligible if the prevalence is low
(data example in Section 6) and strong if the prevalence is high (data example
in Section 7).
Originally, dynamic prediction by landmarking has been proposed to make
survival prognoses ([20]). Similar to [37], we applied the approach for inference
instead. While unproblematic when making predictions, conditioning on survival
up to a certain LM may cause selection bias if the goal is to understand the causal
relationship of exposure and outcome ([38]). This means that the population
at risk at LM l is not a representative sample of the initial study population
sampled at baseline. The difference is due to (unmeasurable) confounding that
has an effect on survival. However, since our target population are not all initially
sampled patients but only those still at risk at LM l selection bias is naturally
avoided ([37]).
A remaining drawback is the fact that the two landmark estimands were iden-
tified with the assumption that the time from exposure to the LM has no impact
on the risk of experiencing the event of interest within the prediction time window.
This assumption corresponds to the well-known Markov assumption ([33], [39]).
If this assumption cannot be made, we must make stronger assumptions about the
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hypothetical intervention. Then, we must assume that it prevents the exposure
exactly at the LM (and within the time window when considering PAF0LM,h),
but also reverses/cures any harm caused by the exposure for individuals who were
exposed before the LM. At the same time the intervention must be specific in the
sense that it reverses only effects caused by the exposure. If the individuals are
healthy besides the exposure-associated health issues such an intervention seems
plausible. However, in data settings where individuals are critically ill, as for
example in an ICU setting, such a specific intervention seems rather unrealistic.
Despite these interpretational limitations in these data settings, the approach
provides information about the best timing of an intervention and identifies the
most vulnerable target populations.
To demonstrate the interpretation of the estimands and performance of the
estimators, we provided a simulation study and two real data examples. Firstly,
we investigated the benefit of a pathogen-specific intervention against V APP.a..
Secondly, we investigated the population-attributable burden of LRR and DR
in a population of breast cancer patients. The two data examples served to
explain the interpretation of the novel approach. We based our interpretation
of PAFLM,h and PAF0LM,h on two distinct hypothetical interventions. The way
the interventions act on exposure may be more or less realistic depending on the
data setting. For example, an intervention that prevents LRR or DR at only one
specific time point is less realistic than an intervention with a long term effect.
In these situations, the estimates can be used to identify high-risk populations
and to describe the burden of exposure on a population level.
A disadvantage of the proposed estimation procedure is the sample size re-
duction at the LMs, which leads to a comparatively large variation of P̂AF 0LM,h
and P̂AFLM,h. The smoothing methods currently available may either result in
a loss of information or a negligible increase in efficiency.
To sum up, we proposed two novel estimands of the PAF to quantify the
burden of time-dependent harmful exposures on a population level. The two
estimands also account for competing risks, filling a gap in the literature ([40]).
Finally, our innovative way of using dynamic prediction and landmarking allows
for adjustment of time-varying confounding in a straightforward way.
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l (LM) l+h         0
 Time since study entry
Figure 1: Illustration of the two different types of interventions. Intervention
1 corresponds to the estimand defined by conventional dynamic prediction and
landmarking, PAFLM,h, intervention 2 corresponds to the estimand defined by
its’ extension, PAF0LM,h.
Figure 2: Cause-specific Weibull hazard rates with a direct effect of exposure
due to an increased hazard of the event of interest with exposure. The hazard of
exposure was α01 = 0.06 and time constant.
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Figure 3: Simulation of a no-effects extended illness-death model with constant
hazards (α01(t) = 0.005, α02(t) = 0.02, α03(t) = 0.02, α14(t) = 0.02, and α15(t) =
0.02). Each sample consists of 10,000 observations. The time window was the
approximate mean time at risk (30 time points). The summary comprises the
mean, median and the first and third quartiles of 100 runs at each LM.
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Figure 4: Simulation of an extended illness-death model with direct effect of the
exposure on the risk to experience the event of interest with time-varying cause-
specific Weibull hazard rates (the cause-specific hazards are shown in Figure 2).
Each sample consists of 2,000 observations. The time window was the approx-
imate mean time at risk (8 time points). The summary comprises the mean,
median and the first and third quartiles of 100 runs at each LM.
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Figure 5: Total number of unexposed and exposed patients at each LM of our
sample (n=7221) of the OUTCOMEREA database, and the number of ICU death
cases within 15 days in each group.
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Figure 6: Unadjusted relative risk of death (left panel) and population-
attributable fraction (right panel) within 15 days depending on the infection
state at the LM. The dashed black lines are the pointwise 95%-CI intervals of
the separate models (separate, non smoothed estimates). The dashed grey lines
are the bootstrap CIs of the supermodels (smoothed estimates).
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Figure 7: Unadjusted estimates of PAFLM,h and PAF0LM,h (left panel) and the
adjusted estimates (right panel) of our sample of the OUTCOMEREA database.
The dashed lines are the pointwise 95%-CI intervals of the separate models of
PAFLM,h (black) and PAF0LM,h (grey).
26
Figure 8: Adjusted estimates of PAFLM,h and PAF0LM,h of LRR (left panel)
and DR (right panel) of the TEAM trial data sample. The dashed lines are
the pointwise 95%-CI intervals of the separate models of PAFLM,h (black) and
PAF0LM,h (grey).
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